NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics said today it has received global exclusive rights from Johns Hopkins University School of Medicine to commercialize a molecular diagnostic test.
The licensing agreement grants Iverson rights to a test for assessing cardiovascular risk in men and women and infertility risk in women. According to Iverson, research by Annabelle Rodriguez-Oquendo at the School of Medicine suggests that mutations within the scavenger receptor class B type 1 (SR-B1) gene is associated with heart disease risk and hormonal and fertility problems in women.
"The importance of finding gene variants that affect the metabolism of cholesterol, especially the healthy fraction, and hormones — hence causing disease — is incredibly important for personalized medicine," Leroy Hood, a co-founder of the Institute for Systems Biology and a member of Iverson's board, said in a statement. "This agreement between Iverson and Johns Hopkins is a wonderful example of a diagnostic test that could significantly improve the health of many patients throughout the world."
Financial and other terms were not disclosed.